W
hat should any researcher expect from a journalist beyond the keen intelligence needed to see the newsworthiness of the researcher's work, and the ability to spell his or her name correctly?
For some scientists, the answer is probably 'Not much' . Many tend to think of science journalism as a kind of public-relations service, existing purely to explain new scientific findings to the masses. They may well enjoy reading the results, and give points for a writer's ability to convey the excitement of a discovery, but they will mainly judge an article on its scientific accuracy.
On top of this, some will see science journalism as an ally, useful for shaping the public's understanding of science-related issues such as nuclear proliferation, stem cells or genetically modified crops -and, not incidentally, for making the case for a thriving research enterprise to public and politicians alike.
And a minority, moving beyond perceived self-interest, will point to the deeper value of journalism, which is to cast a fair but sceptical eye over everything in the public sphere -science included. This kind of scrutiny is easy for researchers to applaud when a news report questions dodgy statistics, say, or dubious claims about uncertainties in evolution. It is not so easy when the story takes a critical look at sloppy animal-research practices, overblown claims about climate change or scientists' conflicts of interest. But such examinations are to the benefit of the enterprise as a whole: society needs to see science scrutinized as well as regurgitated if it is to give science its trust, and journalists are an essential part of that process.
At the moment, unfortunately, journalism's future is far from clear. At the 6th World Conference of Science Journalists, which will be held next week in London, and of which Nature is a sponsor, there will probably be many attendees wondering if this is journalism's swan song. Readers -and small ads, once a reliable earner -are migrating to the Internet. New business models in which papers are given away have caused damaging dislocations in some markets, as in Denmark.
This contraction is perhaps particularly bad news for journalists with specialist beats such as science -the kind of journalists who need an informed understanding of what they are writing about, and know which experts can provide context, and where appropriate criticism, of new results. But publishers tend to see that kind of expertise as a luxury when money is tight, especially when the same space can be easily filled with material from press releases and wire services.
Scientists can do little to stem this bloodletting. But whatever they can do to engage with those caught up in it, and ensure that questioning and informed science journalism persists, will be worthwhile. If there is to be a transition to new -perhaps philanthropic -business models for in-depth reporting or new types of analytical media, science journalism will integrate into them all the better if scientists are taking an active interest in its health. And if the future of the media truly is a dire landscape of top-100 lists, shouting heads and minimal attention span, then such efforts might at least defer the grim end.
Even amid the turmoil, however, scientists can help ensure that reporting about science continues to be both informed and accurate. They can start by recognizing that they will increasingly be talking to reporters who have no experience in science at all. A good start would be to have a look at the advice for academics speaking to journalists provided by Brad DeLong and Susan Rasky at the University of California, Berkeley (http://tinyurl.com/nljleo). Scientific societies, meanwhile, should redouble their efforts to help journalists working under a tight deadline find the experts they need to understand a subject.
Looking farther down the road, the scientific community should work with journalism schools and professional societies to ensure that journalism programmes include some grounding in what science is, and how the process of experiment, review and publication actually works.
Science and journalism are not alien cultures, for all that they can sometimes seem that way. They are built on the same foundationthe belief that conclusions require evidence; that the evidence should be open to everyone; and that everything is subject to question. Both groups are comprised of professional sceptics. And whether it's directed towards an experiment or a breaking news story, each can appreciate the other's critical eye. 
Orphan giant
Strong advocacy is needed if progress is to be made against tuberculosis.
I
t was difficult to avoid a sense of despair after last week's Pacific Health Summit, in Seattle, Washington. The meeting -an annual gathering of researchers, public-health policy-makers, drug regulators and heads of non-governmental organizations, industry and funding institutions -was focused this year on tuberculosis (TB). As presentation followed presentation, the overwhelming scale of the challenge became all too evident. The global economic downturn is exacerbating both the burden of the disease and the obstacles to finding resources to cope with it.
About one-third of the world's population carries the bacterium that causes TB, Mycobacterium tuberculosis, and roughly 10% of these people will go on to develop the disease. Because drug courses can last for a year or more, most people do not complete their treatment, and the growth of resistance is therefore inevitable. Strains of M. tuberculosis are now appearing that are resistant not just to the front-line drugs used in initial treatment but also to the second-line drugs used to treat people who have become resistant, as in the case of the 'extensively drug-resistant tuberculosis' first recognized in 2005. As a recent review article dauntingly but appropriately put it, responding to the issue of resistance requires "a comprehensive approach incorporating innovation from the political, social, economic and scientific realms" (M. Jassal and W. R. Bishai Lancet Infect. Dis. 9, 19-30; 2009) .
Happily, there are some signs of progress. The World Health Organization points out that existing drugs and diagnostics can still make a difference if applied properly. And major improvements in tackling the disease would come from a more joined-up approach with the diagnosis and treatment of HIV/AIDS, which often occurs together with TB.
Unhappily, many of these measures require trained staff, welldesigned buildings and procedures that minimize the spread of infection -resources that simply aren't available in many regions of the world.
Despite donations of vaccines by industry, price-tiering in poorer regions, progress in clinical trials, advanced market-commitment mechanisms and increases in research funding by organizations such as the US National Institutes of Health, the scale of funding remains dwarfed by the challenges. What progress has been made in research simply clarifies just how inadequate our knowledge is. Researchers have only a basic understanding of how the bacterium affects the various parts of the body, and the heterogeneity of its make-up and behaviour is reflected in the spectrum of progressions from infection to active TB. Furthermore, little is known about how the human body responds to M. tuberculosis infection and the bacterium can mutate up to a thousand times faster as it adapts to antibiotic attack and other stressors.
As Anthony Fauci, head of the US National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, stated at the meeting in his overview of the science, generations of advances in research and technology have bypassed TB research. That is beginning to change, but the timescale involved from research to the rolling out of new drugs and biomarkers is alarmingly large given the immediacy of the threats and the complexity of the organism.
Why hasn't more progress been made? According to Margaret Chan, head of the World Health Organization, the field has been too isolated and inward-looking, and needs to learn lessons from the approach to HIV/AIDS by reaching out and finding highly effective champions. Easily said. But the nine million people who develop active TB every year could only agree that the need to capture the world's imagination and support is urgent.
■ into effect on 1 May, 2008. The index incorporates data on how complete the cities' disclosures are, whether they are timely, what measures have been taken in response and whether the disclosures are user-friendly. The potential maximum score is 100. However, the average score for 2008 was only 30, and just four cities scored more than 60.
The two NGOs hope that the ranking will pressure local governments to recognize and be more responsive to the kind of situation that developed in Yangzong Lake in southern China. From 2001 to 2008, the lake -which supplied drinking water for 26,000 peoplewas polluted with arsenic by a chemical company, despite fines and promises of action from local officials.
The index is also intended to make role models out of the bestperforming local governments. In each of eight categories, the IPE designated a top scorer. Taken together, they form a 'dream team' that scored 89.5 points. "This shows that a high level of information disclosure is possible in China, " says Wang Jingjing at the IPE.
The system has limitations, however. It can only report on cases already recognized in official documents. That is not often an issue, says Wang, and an official source is usually available when the IPE hears of a complaint. But the group has no authority to push for further investigation if information is not available. Only 89 of 113 local environmental protection offices returned their calls.
A deeper problem is that the environmental laws themselves are not clear on crucial issues such as penalties for non-compliance. And in any case, the bar is pretty low. For example, Beijing ranks as one of the most transparent cities on the list, even though allegations that officials were manipulating data ahead of the Olympics have been met with denial, and little in terms of explanation (see Nature doi:10. 1038/news.2009.578; 2009) .
Although it is easy to be sceptical, local newspapers are paying attention to the index. In a face-saving society, local bureaucrats might now have to explain why they are at the bottom of the list. "The first thing to do is encourage public participation, " says Wang. "But to do that people have to know what is happening. "
The effort will also give central and local lawmakers a better idea of what is happening, and enable them to see whether laws need to be changed to ensure that China can make good on its intentions. ■ "The timescale involved from research to the rolling out of new drugs and biomarkers is alarmingly large."
